Determination of Biopsy Yield That Optimally Detects Eosinophilic Gastritis and/or Duodenitis in a Randomized Trial of Lirentelimab is a research paper published in Clinical Gastroenterology and Hepatology (2021). On theSindex it has a DataRank of 1.3. It has been cited 57 times, with 34 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.609
From this paper's citation signal
Citation Network Contribution
0.650
From 24 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 34 citers.
NIAID NIH HHS
Grant: U54 AI117804
National Institutes of Health
Grant: R01-AI140133
NIAID NIH HHS
Grant: R01 AI140133
National Institutes of Health
Grant: 5R01AI140133-03
SLC9A3 regulation of esophageal dilated intercellular spaces in EoE Subtypes
National Institutes of Health
Grant: 5U54AI117804-03
Consortium of Eosinophilic Gastrointestinal Disease Researchers
Shire
Grant: unidentified
unidentified
American Partnership for Eosinophilic Disorders
GlaxoSmithKline
Sanofi
Takeda Pharmaceuticals U.S.A.
AstraZeneca
Shire
Eli Lilly and Company
American Academy of Allergy Asthma and Immunology
Mayo Clinic
FWCI
8.12
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals